A Diagnostics & Imaging Week
Enigma Diagnostics (Porton Down, UK), a decentralized and point-of-care molecular diagnostics company, reported that it has signed a term sheet for two patent license agreements with Roche Molecular Systems (Basel, Switzerland).
The licenses will provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and will allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary in vitro diagnostics on a worldwide basis, complementing Enigma's existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.
Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza and MRSA. These tests will be combined with Enigma's revolutionary and fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.
Financial terms were not disclosed.